BioArctic Reports Record Financial Results in 2025

Leqembi approved in over 50 markets, with growing sales and regulatory progress

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

BioArctic, a Swedish biopharmaceutical company, reported record financial results for 2025, with an operating profit of over SEK 1.2 billion. The company's lead drug, Leqembi, was approved in more than 50 markets during the year, and sales continued to grow each quarter despite some currency headwinds. BioArctic also advanced its pipeline, nominating new drug candidates in ALS and Parkinson's disease, and continued to invest in its BrainTransporter technology to enhance the delivery of antibodies to the brain.

Why it matters

BioArctic's strong financial performance and progress with Leqembi and its pipeline demonstrate the company's ability to successfully develop and commercialize innovative treatments for neurodegenerative diseases. The continued advancement of Leqembi and BioArctic's other projects could lead to new treatment options for patients suffering from Alzheimer's, Parkinson's, ALS, and other debilitating conditions.

The details

In the fourth quarter of 2025, BioArctic reported net revenues of SEK 184.0 million, of which SEK 127.0 million came from Leqembi royalties and SEK 51.1 million from an agreement with Novartis. The company's operating profit for the quarter was SEK 33.2 million. For the full year 2025, BioArctic achieved an operating profit of over SEK 1.2 billion, more than doubling its cash position to SEK 2.19 billion. The company's board has proposed a dividend of SEK 2.00 per share. Leqembi, BioArctic's Alzheimer's drug developed with partner Eisai, was approved in Brazil, Canada, and the UK during the fourth quarter. Eisai also submitted applications for subcutaneous initiation treatment in Japan and the US, where the FDA granted priority review. BioArctic also advanced its pipeline, nominating new drug candidates in ALS and Parkinson's disease, and continued to invest in its BrainTransporter technology to enhance drug delivery to the brain.

  • In October, the subcutaneous version of Leqembi, called Leqembi Iqlik, was launched for maintenance treatment in the US.
  • In November, a 15% price reduction for Leqembi was implemented in Japan.
  • In December, Eisai submitted a Marketing Authorisation Variation to the EMA for intravenous maintenance dosing every four weeks with Leqembi.
  • In early January 2026, BioArctic received a new approval for Leqembi and had two regulatory applications granted priority review.

The players

BioArctic AB

A Swedish research-based biopharma company focusing on innovative treatments for neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS. The company invented Leqembi, the first drug proven to slow the progression of early Alzheimer's disease.

Eisai

BioArctic's partner responsible for regulatory interactions and commercialization of Leqembi globally.

Gunilla Osswald

CEO of BioArctic AB.

Anders Martin-Löf

CFO of BioArctic AB.

Oskar Bosson

VP of Communications and Investor Relations at BioArctic AB.

Got photos? Submit your photos here. ›

What they’re saying

“2025 was a fantastic year for BioArctic, with record financial results, another partnership and new projects. We set a new course for the future and entered a new era, the growth era.”

— Gunilla Osswald, CEO, BioArctic AB (BioArctic)

What’s next

BioArctic expects to complete the Phase 2a study for its Parkinson's disease drug exidavnemab in 2026 and begin planning for a Phase 2b study. The company also plans to present new data on its BrainTransporter technology within the coming year.

The takeaway

BioArctic's strong financial performance, regulatory progress with Leqembi, and continued pipeline advancement demonstrate the company's ability to develop innovative treatments for neurodegenerative diseases. The company's focus on enhancing drug delivery to the brain through its BrainTransporter technology also holds promise for improving the efficacy of future therapies.